What's new in DyslipidemiaLast update of the site: Tuesday June 21, 2022

Sabbari Maryam et al. | BMC Public Health 2021; 22(1): 795
Currently, one third of the world’s population is overweight or obese, and it is projected that...
Kristen J. Bubb et al. | Expert Review of Cardiovascular Therapy...
Dyslipidemia therapeutics have primarily focused on lowering levels of low-density lipoprotein cholesterol....
Chan Joo Lee MD et al. | Journal of the American Heart Association...
Incremental risk elevation and its dependency on low‐density lipoprotein cholesterol levels were...
Marc Evans MD et al. | Diabetes, Obesity & Metabolism 2022;...
Approximately one‐third of patients with type 2 diabetes (T2D) worldwide also have cardiovascular...
Pan Junqiang et al. | Journal of Health, Population and Nutrition...
Dyslipidemia is defined as the prevalence of adverse blood concentrations of any of the followings: triglycerides...
Nazarzadeh, Milad et al. | Journal of Hypertension 2022; 40(5):...
Individual participant data (IPD) meta-analyses are particularly powerful for investigation of stratified...
Aditya Bhat et al. | European Journal of Clinical Investigation...
Atrial fibrillation (AF) is the most prevalent dysrhythmia globally, with pronounced epidemiological...
Olta Allkanjari et al. | Phytotherapy Research 2022; 36(6): 2583-604...
In Italy, the use of food supplements containing botanicals is currently regulated by the Ministerial...
Tao Li-Chan et al. | Cardiovascular Diabetology 2022; 21(1):...
Cardiovascular disease (CVD) is a leading cause of morbidity and mortality worldwide, posing serious...
Tapoi Laura et al. | BMC Nephrology 2022; 23(1): 176
The coronavirus disease (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)...

Bibliographical searchFocus and target to your research of scientific data

Research by journal
811 articles currently available
A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | 0-9

Top articlesThe 5 most read articles

Kristen J. Bubb et al. | Expert Review of Cardiovascular Therapy...
Dyslipidemia therapeutics have primarily focused on lowering levels of low-density lipoprotein cholesterol. However, many patients continue to experience cardiovascular events, despite effective lowering...
Sabbari Maryam et al. | BMC Public Health 2021; 22(1): 795
Currently, one third of the world’s population is overweight or obese, and it is projected that this incidence will increase to 57.8% by 2030obese [1]. Recent estimates indicate that the prevalence...
Nazarzadeh, Milad et al. | Journal of Hypertension 2022; 40(5):...
Individual participant data (IPD) meta-analyses are particularly powerful for investigation of stratified treatment effects. In addition to being able to verify the information and standardize rules and...
Tao Li-Chan et al. | Cardiovascular Diabetology 2022; 21(1):...
Cardiovascular disease (CVD) is a leading cause of morbidity and mortality worldwide, posing serious public health challenges and placing an economic burden on patients [1]. Although several risk factors...
Aditya Bhat et al. | European Journal of Clinical Investigation...
Atrial fibrillation (AF) is the most prevalent dysrhythmia globally, with pronounced epidemiological coupling seen with advancing age, a group with a higher prevalence of cardiometabolic risk factors and...